Top ten stories in the pharmaceutical industry this week
pharmafile | August 19, 2016 | News story | Medical Communications | pharmafile, top ten
The end of another week, and from huge expansions and investments to some shocking and saddening tragedies, it’s been a big week as usual in the pharma industry. Check out the ten most popular articles on Pharmafile over the last week:
10. MSD to cut 148 jobs at Pennsylvania plant
Cuts related to the company’s discontinuation of heart drug Zontivity
9. J&J loses Remicade patent fight, pledges to continue fight against biosimilars
A Massachusetts Federal Court ruled in favour of biosimilar makers Celltrion and Hospira, declaring Janssen’s Remicade ‘471 patent is invalid
8. Novartis invests €100 million to expand French manufacturing plant
Expansion will increase production capacity by 70% and create 100 new jobs at the Huningue facility
7.NICE recommends removal of Afinitor and Imbruvica from Cancer Drugs Fund
NICE have made a preliminary decision to remove the drugs made by Novartis and Janssen from the Cancer Drugs Fund as they are “not cost effective”
6. 13 deaths in Aurinia’s lupus drug trial despite hitting Phase II target
Canadian biotech’s stocks plummet despite voclosporin’s trial success
5. Untested cancer drug suspected cause of three deaths at German alternative medicine centre
Public prosecutor investigating whether use of 3-Bromopyruvate constitutes involuntary manslaughter
4. Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
A new study published in JAMA claims that the range of PCSK9 inhibitor cholesterol lowering therapies are not cost effective
3. The impact of Brexit on the pharmaceutical industry: some preliminary considerations
The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new era in the history of UK-EU relations.
2. Thousands to benefit with new anti-clotting drug recommendation, says NICE
AstraZeneca’s Brilique (ticagrelor) has been recommended for up to three years after someone has had a heart attack to reduce the risk of further heart attack or stroke
1. GSK, Roche and Novo back $86 million immuno-oncology startup
Major industry players help fund development of the firm’s anti-CD47 antibody portfolio
Related Content
Pharmafile.com’s top 10 news stories of the week
COVID-19 news has slowed down in the last week, allowing different pharma developments to take …
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
The Autumn 2020 edition of Pharmafile is available to read for free online now!
The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 …
